Sjögren Disease

Etiology and Clinical Context

Sjögren disease may be primary or occur with rheumatoid arthritis, SLE, and other autoimmune disorders. It is more common in women and typically presents in adulthood, though it can occur across the lifespan. Symptoms of dryness are common in the general population, especially with medications and aging, so diagnostic attribution requires objective evidence and clinical context.

The disorder extends beyond a local loss of tears and saliva: systemic immune activation may affect peripheral nerves, lungs, kidneys, joints, and blood vessels. Marked fatigue may not correlate directly with glandular secretion measurements.

Epidemiology and Risk Profile

Recognition may be delayed when dental problems, fatigue, neuropathy, or electrolyte disturbances precede a clear complaint of dryness. Medication use and coexisting autoimmune disease can also complicate attribution, making the sequence of symptoms clinically useful.

Pathophysiology

Exocrine epithelial and lymphocytic injury

Immune-cell infiltration of lacrimal and salivary glands damages and dysregulates secretory epithelium. CD4-positive T cells, B cells, interferon-associated pathways, and local cytokines reinforce inflammation. Reduced tear and saliva production undermines corneal protection, oral lubrication, and antimicrobial defense (Gelber et al., 2019).

B-cell hyperactivity and systemic manifestations

Persistent B-cell activation contributes to anti-SSA/Ro, sometimes anti-SSB/La, rheumatoid factor, and hypergammaglobulinemia. Cryoglobulins and complement consumption may mark more systemic disease and are linked with some lymphoproliferative-risk phenotypes. Anti-SSB/La in isolation is not part of the weighted 2016 ACR/EULAR classification criteria.

Extraglandular injury

Tubulointerstitial nephritis may impair distal nephron acid secretion, causing distal renal tubular acidosis and hypokalemia. Pulmonary inflammatory disease may cause interstitial lung disease, while peripheral neuropathy or small-fiber neuropathy can arise from immune-mediated nerve injury. A minority of patients develop B-cell lymphoma after prolonged immune dysregulation.

From Gland Injury to Complications

Immune process	Organ dysfunction	Expected manifestation
Lymphocytic lacrimal-gland infiltration	Reduced tear-film production	Keratoconjunctivitis sicca (dry eye), ocular surface injury, possible keratitis
Autoimmune salivary-gland dysfunction	Less salivary lubrication and antimicrobial protection	Xerostomia, dental caries, candidiasis, dysphagia with dry foods
B-cell hyperactivity and immune-mediated tissue injury	Systemic organ involvement	Purpura, neuropathy, renal tubular acidosis, interstitial lung disease
Sustained lymphoproliferative stimulation	Minority develop B-cell lymphoma	Persistent gland enlargement, unexplained adenopathy or systemic symptoms

Glandular symptoms and systemic disease do not always progress together. Kidney or lung involvement may require investigation even when dryness is modest, while severe ocular symptoms may persist without substantial systemic inflammation.

Clinical Manifestations

Dry eyes can cause burning, grittiness, fluctuating vision, and corneal injury. Dry mouth produces difficulty swallowing dry foods, increased dental caries, oral candidiasis, or recurrent parotid swelling. Patients may report fatigue, nonerosive arthralgia, Raynaud phenomenon, purpura, neuropathic pain, cough, or dyspnea.

Ask about drugs that cause sicca symptoms, prior head/neck radiation, infection-related disease, dehydration, and other competing explanations. The absence of striking dryness does not eliminate systemic Sjögren disease when extraglandular features and objective testing suggest it.

Diagnostic Evaluation

Targeted evaluation may include anti-SSA/Ro, ANA, rheumatoid factor, CBC, renal function/electrolytes, urinalysis, and complement studies in systemic presentations. The 2016 ACR/EULAR classification criteria assign 3 points each for anti-SSA/Ro positivity and a labial salivary gland focus score of at least 1, plus 1 point each for abnormal ocular staining, Schirmer testing, or unstimulated salivary flow. A total score of at least 4 is needed for classification in eligible patients without specified exclusions; these criteria are not identical to clinical diagnostic judgment (Shiboski et al., 2017).

A Schirmer test of 5 mm or less in five minutes supports reduced tear production. A labial salivary gland focus score of at least 1 focus per 4 mm² provides histologic evidence of focal lymphocytic sialadenitis. Salivary ultrasound may support assessment but should not automatically replace biopsy in a seronegative, otherwise uncertain case (Price et al., 2025).

Persistent salivary enlargement, new lymphadenopathy, low C4, cryoglobulinemia, or monoclonal gammopathy warrants evaluation for lymphoma or another lymphoproliferative disorder. Assess for renal tubular acidosis with bicarbonate and potassium if symptoms or laboratory patterns suggest it.

Expected Findings and Diagnostic Interpretation

Test or finding	Interpretive value	What cannot be concluded
Anti-SSA/Ro	Strongly weighted in 2016 ACR/EULAR classification and often supports the systemic autoimmune phenotype	A negative result does not exclude disease; isolated anti-SSB/La is not a classification item
Schirmer ≤5 mm/5 min	Demonstrates reduced basal tear production	Dryness can also reflect medications, aging, contact lenses or other ocular conditions
Ocular staining score ≥5 or van Bijsterveld ≥4	Identifies ocular surface damage consistent with keratoconjunctivitis sicca	Corneal staining is not specific for autoimmune etiology
Unstimulated whole saliva flow ≤0.1 mL/min	Objectively demonstrates reduced salivary secretion	Low flow may result from anticholinergic medications, dehydration or other gland conditions
Labial salivary gland focus score ≥1 per 4 mm²	Focal lymphocytic sialadenitis supports an autoimmune glandular process	Interpretation depends on adequate tissue and experienced pathology assessment
Electrolytes, urinalysis, C3/C4 and immunoglobulins	Low bicarbonate and hypokalemia suggest renal tubular acidosis; low complement or monoclonal findings can indicate systemic risk	These findings are not obligatory for gland-limited disease

A patient without anti-SSA/Ro can still have a persuasive autoimmune phenotype when a qualifying gland biopsy and objective measures of dryness are present. When tests disagree, review medication exposures, specimen quality, and classification exclusions before assigning a diagnosis (Shiboski et al., 2017).

Differential Diagnosis

Medication effects, particularly anticholinergic agents, antihistamines, antidepressants and diuretics, frequently contribute to sicca symptoms. Consider dehydration, diabetes, age-related ocular disease, contact lens exposure, prior head/neck radiation, hepatitis C or HIV infection, sarcoidosis, IgG4-related disease, amyloidosis, and graft-versus-host disease when supported by context. Some are specifically excluded from the 2016 primary Sjögren classification framework. Dry eyes or mouth accompanying RA or SLE may also reflect overlapping autoimmune processes rather than an entirely independent primary disorder.

Diagnostic Limitations and Reassessment

An isolated positive anti-SSA/Ro result does not establish that a patient’s fatigue, dryness or neuropathy is caused by Sjögren disease; conversely, seronegative disease can be supported by objective gland dysfunction and biopsy. Objective testing should account for medication exposure and testing conditions. Reassessment must cover surface injury and dental health, not only autoantibodies. New neuropathy, hypokalemia, progressive cough, purpura, low C4 or persistent salivary gland enlargement raises the priority of systemic evaluation or lymphoma assessment (Price et al., 2025).

What to assess at follow-up

• Eye discomfort, visual changes and ocular-surface complications; ensure ophthalmology involvement when needed.
• Oral dryness, dental caries, candidiasis and swallowing difficulty; assess prevention and secretion support.
• New neuropathy, pulmonary symptoms, electrolyte or urinary abnormalities, purpura, or swollen glands.
• Persistent unilateral gland enlargement, lymphadenopathy or unexplained systemic symptoms requiring evaluation for lymphoproliferative disease.

Management and Mechanistic Rationale

Local therapy addresses secretion loss and surface injury: preservative-free artificial tears, ocular anti-inflammatory strategies as indicated, saliva substitutes, oral hydration, dental prevention, and prescription secretagogues such as pilocarpine or cevimeline for suitable patients. Muscarinic agonists stimulate residual glandular secretion rather than reversing autoimmune destruction.

Hydroxychloroquine may be considered for selected systemic manifestations such as inflammatory joint symptoms but has inconsistent evidence for improving dryness or fatigue (Ramos-Casals et al., 2020). Systemic glucocorticoids and other immunomodulatory agents should be reserved for specific active organ disease, weighing limited efficacy data and treatment risk rather than treating sicca symptoms with broad immunosuppression.

Complications and Red Flags

Complications include corneal ulceration, visual impairment, accelerated dental disease, parotid infection, interstitial lung disease, renal tubular acidosis, neuropathy, vasculitis, and lymphoma. Symptoms such as persistent unilateral gland swelling, B symptoms, palpable purpura, and unexpected lymphadenopathy need further investigation.

Regular eye and dental care remains important even when systemic disease appears stable. In patients with coexisting RA or SLE, those conditions may also shape organ manifestations and treatment decisions.

Clinical Reasoning Priorities

Separate three clinical domains: glandular dysfunction, systemic immune activity, and lymphoproliferative risk. Each requires different examination findings and investigations.

Examine a patient’s medication list before diagnosing autoimmune sicca. A seronegative patient with convincing objective gland dysfunction may still warrant a biopsy-based assessment, while an isolated anti-SSA/Ro result cannot by itself explain every symptom.

Applied Clinical Reasoning

Clinical question: A patient reports gritty eyes, frequent dental caries, and new muscle cramps. Potassium is 2.8 mmol/L with a normal-anion-gap metabolic acidosis. What links these findings?

Reasoning: Exocrine disease plus hypokalemic non-anion-gap acidosis suggests Sjögren-related tubulointerstitial injury with distal renal tubular acidosis. Confirm the renal acidification defect, assess kidney risk and other causes, and evaluate objective ocular/salivary findings and autoimmunity.

High-Yield Distinctions

Finding	Mechanistic meaning	Practice implication
Dryness while using anticholinergic drugs	Reduced secretion can be pharmacologic	Review medications before attributing sicca to autoimmunity
Anti-SSA/Ro negative, abnormal gland biopsy	Seronegative disease is possible	Integrate objective evidence instead of relying on one antibody
Persistent parotid enlargement and low C4	B-cell activation with possible lymphoma-risk phenotype	Assess promptly for lymphoproliferative disease

Related YourDNP Guides

• Back to Pathophysiology
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Musculoskeletal and Rheumatic Foundations

---

---

References

Gelber, A. C., Levine, S. M., & Darrah, E. (2019). Inflammatory rheumatic diseases. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed., Chapter 24). McGraw-Hill Education. AccessMedicine

Price, E. J., Benjamin, S., Bombardieri, M., Bowman, S., Carty, S., Ciurtin, C., Crampton, B., Dawson, A., Fisher, B. A., Giles, I., Glennon, P., Gupta, M., Hackett, K. L., Larkin, G., Ng, W.-F., Ramanan, A. V., Rassam, S., Rauz, S., Smith, G., . . . Walsh, S. B. (2025). Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology, 64(2), 396–408. https://doi.org/10.1093/rheumatology/keae218

Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., Bootsma, H., De Vita, S., Dörner, T., Fisher, B. A., Gottenberg, J.-E., Hernandez-Molina, G., Kocher, A., Kostov, B., Kruize, A. A., Mandl, T., Ng, W.-F., Retamozo, S., Seror, R., Shoenfeld, Y., Sisó-Almirall, A., Tzioufas, A. G., . . . Mariette, X. (2020). EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 79(1), 3–18. https://doi.org/10.1136/annrheumdis-2019-216114

Shiboski, C. H., Shiboski, S. C., Seror, R., Criswell, L. A., Labetoulle, M., Lietman, T. M., Rasmussen, A., Scofield, H., Vitali, C., Bowman, S. J., Mariette, X., & International Sjögren’s Syndrome Criteria Working Group. (2017). 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis & Rheumatology, 69(1), 35–45. https://doi.org/10.1002/art.39859